James S Chang, MD
Hematology/Oncology · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Permanente Medical Group Inc · 10,928 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chang’s office at (408) 851-1000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A86238 · Current
Licensed to practise in California · since 2004 · expires 2028-02-29 · Mount Sinai School of Medicine of New York University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$1,855,371
Pharmacies billed $1,855,371 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (47 of 695) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%.
535 generic and 160 brand-name prescriptions · $1,855,371 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ibrance | 58 | $897,470 | $15,474 |
| Calquence | 19 | $235,030 | $12,370 |
| Tagrisso | 11 | $188,753 | $17,159 |
| Inlyta | 12 | $170,944 | $14,245 |
| Nivestym | 11 | $9,030 | $821 |
See all 15 drugs
| Ibrance | 58 | $897,470 | $15,474 |
| Calquence | 19 | $235,030 | $12,370 |
| Tagrisso | 11 | $188,753 | $17,159 |
| Inlyta | 12 | $170,944 | $14,245 |
| Nivestym | 11 | $9,030 | $821 |
| Anastrozole | 222 | $6,204 | $28 |
| Exemestane | 22 | $1,823 | $83 |
| Hydroxyurea | 27 | $1,086 | $40 |
| Tamoxifen Citrate | 34 | $880 | $26 |
| Letrozole | 32 | $868 | $27 |
| Lorazepam | 24 | $315 | $13 |
| Oxycodone-Acetaminophen | 12 | $243 | $20 |
| Hydrocodone-Acetaminophen | 17 | $217 | $13 |
| Levothyroxine | 11 | $198 | $18 |
| Ondansetron | 13 | $135 | $10 |
Year by year
| 2024 | 695 | 156 | 7% (47) | 23% | $1,855,371 |
| 2023 | 688 | 151 | 10% (66) | 23% | $2,122,274 |
| 2022 | 588 | 135 | 3% (18) | 27% | $2,076,512 |
| 2021 | 597 | 145 | 8% (49) | None | $1,664,016 |
| 2020 | 545 | 128 | 9% (50) | 25% | $1,318,504 |
| 2019 | 398 | 114 | 6% (25) | 20% | $776,183 |
| 2018 | 419 | 118 | 7% (28) | 16% | $582,716 |
| 2017 | 485 | 142 | 8% (40) | None | $222,963 |
| 2016 | 688 | 175 | 6% (41) | 26% | $1,310,656 |
| 2015 | 759 | 166 | 8% (64) | 25% | $1,287,599 |
| 2014 | 633 | 154 | 12% (77) | None | $1,055,875 |
| 2013 | 611 | 125 | 12% (76) | 18% | $599,770 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Ibrance | 63 | $880,428 | $13,975 |
| Piqray | 14 | $309,812 | $22,129 |
| Calquence | 20 | $247,560 | $12,378 |
| Tagrisso | 12 | $183,144 | $15,262 |
| Lynparza | 11 | $96,521 | $8,775 |
| Anastrozole | 217 | $5,532 | $25 |
| Exemestane | 22 | $1,947 | $88 |
| Tamoxifen Citrate | 28 | $1,032 | $37 |
| Hydroxyurea | 20 | $974 | $49 |
| Letrozole | 25 | $804 | $32 |
| Dronabinol | 12 | $599 | $50 |
| Hydrocodone-Acetaminophen | 40 | $438 | $11 |
| Levothyroxine | 13 | $273 | $21 |
| Ondansetron | 20 | $197 | $10 |
| Prednisone | 12 | $155 | $13 |
| Lorazepam | 19 | $149 | $8 |
2022: 11 drugs
| Ibrance | 80 | $1,048,632 | $13,108 |
| Lynparza | 15 | $228,782 | $15,252 |
| Tagrisso | 12 | $202,145 | $16,845 |
| Anastrozole | 209 | $5,062 | $24 |
| Exemestane | 15 | $1,361 | $91 |
| Hydroxyurea | 16 | $880 | $55 |
| Tamoxifen Citrate | 14 | $738 | $53 |
| Letrozole | 15 | $309 | $21 |
| Triamcinolone Acetonide | 13 | $247 | $19 |
| Ondansetron | 19 | $180 | $9 |
| Lorazepam | 22 | $165 | $7 |
2021: 13 drugs
| Ibrance | 75 | $944,911 | $12,599 |
| Lynparza | 15 | $222,760 | $14,851 |
| Tagrisso | 12 | $199,131 | $16,594 |
| Xarelto | 15 | $8,086 | $539 |
| Anastrozole | 197 | $4,795 | $24 |
| Exemestane | 18 | $1,628 | $90 |
| Hydroxyurea | 12 | $663 | $55 |
| Hydrocodone-Acetaminophen | 23 | $381 | $17 |
| Ondansetron | 15 | $380 | $25 |
| Hydrocortisone | 12 | $375 | $31 |
| Prochlorperazine Maleate | 18 | $317 | $18 |
| Letrozole | 13 | $317 | $24 |
| Lorazepam | 24 | $172 | $7 |
2020: 13 drugs
| Ibrance | 70 | $873,218 | $12,475 |
| Tagrisso | 11 | $180,911 | $16,446 |
| Lynparza | 11 | $160,906 | $14,628 |
| Anastrozole | 192 | $4,634 | $24 |
| Exemestane | 12 | $3,651 | $304 |
| Hydrocortisone | 12 | $454 | $38 |
| Letrozole | 18 | $438 | $24 |
| Hydrocodone-Acetaminophen | 22 | $352 | $16 |
| Diphenoxylate-Atropine | 13 | $226 | $17 |
| Morphine Sulfate Er | 12 | $206 | $17 |
| Lorazepam | 19 | $143 | $8 |
| Alendronate | 11 | $114 | $10 |
| Ondansetron | 12 | $100 | $8 |
2019: 8 drugs
| Ibrance | 50 | $645,185 | $12,904 |
| Anastrozole | 194 | $4,740 | $24 |
| Exemestane | 14 | $4,260 | $304 |
| Enoxaparin | 12 | $3,820 | $318 |
| Hydrocortisone | 12 | $462 | $38 |
| Letrozole | 13 | $317 | $24 |
| Hydrocodone-Acetaminophen | 13 | $202 | $16 |
| Alendronate | 13 | $139 | $11 |
2018: 7 drugs
| Ibrance | 22 | $271,155 | $12,325 |
| Exemestane | 18 | $6,213 | $345 |
| Anastrozole | 189 | $5,003 | $26 |
| Hydroxyurea | 12 | $768 | $64 |
| Hydrocortisone | 11 | $412 | $37 |
| Morphine Sulfate Er | 13 | $257 | $20 |
| Alendronate | 11 | $145 | $13 |
2017: 9 drugs
| Exemestane | 17 | $7,985 | $470 |
| Anastrozole | 178 | $5,171 | $29 |
| Hydroxyurea | 22 | $1,723 | $78 |
| Tamoxifen Citrate | 28 | $1,440 | $51 |
| Hydrocodone-Acetaminophen | 16 | $481 | $30 |
| Ondansetron | 21 | $310 | $15 |
| Dexamethasone | 14 | $255 | $18 |
| Prochlorperazine Maleate | 24 | $243 | $10 |
| Alendronate | 16 | $227 | $14 |
2016: 16 drugs
| Revlimid | 31 | $349,964 | $11,289 |
| Zytiga | 30 | $261,018 | $8,701 |
| Ibrance | 19 | $207,622 | $10,927 |
| Gleevec | 23 | $127,203 | $5,531 |
| Xtandi | 13 | $121,761 | $9,366 |
| Anastrozole | 121 | $4,040 | $33 |
| Tamoxifen Citrate | 51 | $2,681 | $53 |
| Hydroxyurea | 22 | $2,023 | $92 |
| Prochlorperazine | 17 | $1,403 | $83 |
| Prednisone | 35 | $1,011 | $29 |
| Hydrocodone-Acetaminophen | 21 | $911 | $43 |
| Ondansetron | 23 | $764 | $33 |
| Prochlorperazine Maleate | 55 | $620 | $11 |
| Acyclovir | 14 | $444 | $32 |
| Letrozole | 12 | $310 | $26 |
| Nystatin | 11 | $163 | $15 |
2015: 22 drugs
| Revlimid | 32 | $378,415 | $11,825 |
| Zytiga | 40 | $323,889 | $8,097 |
| Gleevec | 18 | $132,129 | $7,340 |
| Tarceva | 17 | $122,325 | $7,196 |
| Imbruvica | 12 | $118,368 | $9,864 |
| Neupogen | 12 | $29,249 | $2,437 |
| Anastrozole | 92 | $2,993 | $33 |
| Tamoxifen Citrate | 48 | $2,728 | $57 |
| Anagrelide | 11 | $2,623 | $238 |
| Hydroxyurea | 29 | $2,500 | $86 |
| Prochlorperazine | 25 | $2,197 | $88 |
| Megestrol Acetate | 14 | $1,477 | $106 |
| Prednisone | 49 | $1,227 | $25 |
| Hydrocodone-Acetaminophen | 30 | $1,152 | $38 |
| Morphine Sulfate Er | 17 | $958 | $56 |
| Prochlorperazine Maleate | 54 | $605 | $11 |
| Lidocaine-Prilocaine | 12 | $581 | $48 |
| Dexamethasone | 27 | $541 | $20 |
| Duloxetine | 11 | $463 | $42 |
| Methylphenidate | 13 | $279 | $21 |
| Ondansetron | 17 | $272 | $16 |
| Lorazepam | 13 | $113 | $9 |
2014: 14 drugs
| Revlimid | 39 | $424,383 | $10,882 |
| Zytiga | 32 | $194,778 | $6,087 |
| Gleevec | 16 | $108,009 | $6,751 |
| Anastrozole | 78 | $2,736 | $35 |
| Prochlorperazine Maleate | 63 | $2,670 | $42 |
| Tamoxifen Citrate | 34 | $2,176 | $64 |
| Anagrelide | 13 | $1,793 | $138 |
| Morphine Sulfate Er | 23 | $1,538 | $67 |
| Hydroxyurea | 21 | $1,279 | $61 |
| Hydrocodone-Acetaminophen | 39 | $874 | $22 |
| Dexamethasone | 25 | $477 | $19 |
| Prednisone | 30 | $418 | $14 |
| Diphenoxylate-Atropine | 11 | $288 | $26 |
| Lorazepam | 15 | $133 | $9 |
2013: 16 drugs
| Revlimid | 25 | $268,750 | $10,750 |
| Zytiga | 21 | $119,057 | $5,669 |
| Morphine Sulfate Er | 20 | $2,228 | $111 |
| Prochlorperazine Maleate | 77 | $2,175 | $28 |
| Hydroxyurea | 17 | $1,711 | $101 |
| Anastrozole | 45 | $1,569 | $35 |
| Tamoxifen Citrate | 24 | $1,340 | $56 |
| Diphenoxylate-Atropine | 19 | $718 | $38 |
| Hydrocodone-Acetaminophen | 25 | $525 | $21 |
| Lidocaine-Prilocaine | 12 | $412 | $34 |
| Prednisone | 26 | $353 | $14 |
| Lactulose | 17 | $338 | $20 |
| Temazepam | 22 | $310 | $14 |
| Ondansetron | 14 | $238 | $17 |
| Lorazepam | 19 | $202 | $11 |
| Trazodone | 13 | $89 | $7 |
Money from drug and device companies
$125 in 2019
A payment is not proof that care is biased.
| Celgene | Revlimid | $125 | 1 payment
|
See the published payment
| Celgene | Meals · 2019-11-01 | Revlimid | $125 |
Professional record
- NPI
- 1417068073
- Licence
- CA A86238California A86238: Current · expires 2028-02-29
- Trained
- Icahn School of Medicine at Mount Sinai, 2002
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A862380
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 2100 N Point St, #105, San Francisco, CA, 94123
- NPI first listed
- 2006-08-31
- NPI last updated
- 2021-12-13
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.